Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo (batch 1)

ABSTRACT: Pooled genetic screening with CRISPR/Cas9 has enabled genome-wide high-resolution assignment of genes to phenotypes. To assess the effect of a given genetic perturbation, each sgRNA must be evaluated in hundreds of cells to overcome stochastic genetic drift and obtain robust results. In complex models that display particularly high heterogeneity, such as organoids or tumors transplanted into mice however, sufficient representation typically requires unreasonable scaling, thus preventing genome-wide screens at high resolution. Here we present CRISPR-StAR, a screening paradigm that overcomes intrinsic and extrinsic heterogeneity as well as genetic drift in bottlenecks by leveraging internal controls generated through activating sgRNAs only in half of the progenies of each cell. We use CRISPR-StAR to reveal in vivo-specific genetic dependencies in a genome-wide screen in mouse melanoma. Benchmarking to a conventional screening setup highlights the improved data quality this technology delivers. We anticipate CRISPR-StAR to set a new standard for genetic screening in complex models, foremost in vivo.

ORGANISM(S): Mus musculus

PROVIDER: GSE262307 | GEO | 2024/11/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo (batch 2)

Project description:Pooled genetic screening with CRISPR/Cas9 has enabled genome-wide high-resolution assignment of genes to phenotypes. To assess the effect of a given genetic perturbation, each sgRNA must be evaluated in hundreds of cells to overcome stochastic genetic drift and obtain robust results. In complex models that display particularly high heterogeneity, such as organoids or tumors transplanted into mice however, sufficient representation typically requires unreasonable scaling, thus preventing genome-wide screens at high resolution. Here we present CRISPR-StAR, a screening paradigm that overcomes intrinsic and extrinsic heterogeneity as well as genetic drift in bottlenecks by leveraging internal controls generated through activating sgRNAs only in half of the progenies of each cell. We use CRISPR-StAR to reveal in vivo-specific genetic dependencies in a genome-wide screen in mouse melanoma. Benchmarking to a conventional screening setup highlights the improved data quality this technology delivers. We anticipate CRISPR-StAR to set a new standard for genetic screening in complex models, foremost in vivo.

2024-11-05 | GSE262308 | GEO

CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo

Project description:CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo

| PRJNA1091311 | ENA

CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo (batch 1)

Project description:CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo (batch 1)

| PRJNA1091313 | ENA

CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo (batch 2)

Project description:CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo (batch 2)

| PRJNA1091314 | ENA

Project description:Genome-wide CRISPR screening

| PRJNA752869 | ENA

Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing.

Project description:MotivationTranscriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery. Nevertheless, key limitations of the current drug connectivity-mapping paradigm have been long overlooked, including the lack of effective means to determine optimal query gene signatures.ResultsThe novel approach Dr Insight implements a frame-breaking statistical model for the 'hand-shake' between disease and drug data. The genome-wide screening of concordantly expressed genes (CEGs) eliminates the need for subjective selection of query signatures, added to eliciting better proxy for potential disease-specific drug targets. Extensive comparisons on simulated and real cancer datasets have validated the superior performance of Dr Insight over several popular drug-repurposing methods to detect known cancer drugs and drug-target interactions. A proof-of-concept trial using the TCGA breast cancer dataset demonstrates the application of Dr Insight for a comprehensive analysis, from redirection of drug therapies, to a systematic construction of disease-specific drug-target networks.Availability and implementationDr Insight R package is available at https://cran.r-project.org/web/packages/DrInsight/index.html.Supplementary informationSupplementary data are available at Bioinformatics online.

| S-EPMC6691331 | biostudies-literature

CRISPR-StAR, a paradigm leveraging internal controls, empowers genetic screening in vivo

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-11-05 | GSE262309 | GEO

A genome-wide CRISPR library for high-throughput genetic screening in Drosophila cells

Project description:A genome-wide CRISPR library for high-throughput genetic screening in Drosophila cells

| PRJNA279536 | ENA

RNA-seq and genome-wide CRISPR activation screening

Project description:RNA-seq and genome-wide CRISPR activation screening

| PRJNA917326 | ENA

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in NSCLC

Project description:Human non-small-cell lung cancers (NSCLCs) harboring activating mutations in epidermal growth factor receptor (EGFR) frequently respond to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib. However, the responses are not durable, and the magnitude of tumor regression is variable, suggesting the existence of genetic modifiers of EGFR dependency in EGFR-mutant NSCLCs. Here, we applied a genome-wide CRISPR-Cas9 screening to identify genetic determinants of EGFR TKI sensitivity and uncovered both known and putative candidates. Specifically, we show that knockout of RIC8A, a guanine nucleotide exchange factor (GEF) essential for G-alpha protein activation, enhanced EGFR TKI-induced cell death and prevented acquired resistance. Mechanistically, we demonstrate that RIC8A is a potent positive regulator of the pro-survival YAP signaling pathway, activation of which rescued the EGFR TKI sensitizing phenotype resulting from RIC8A knockout. We also show that knockout of ARIH2, or other components in the Cullin-5 E3 ubiquitin ligase complex, conferred resistance to EGFR inhibition, in part by promoting nascent protein synthesis through METAP2. Together, these data uncover a spectrum of previously unidentified regulators of EGFR TKI sensitivity in EGFR-mutant NSCLC cells, providing insights into the heterogeneity of EGFR TKI treatment responses in EGFR-mutant NSCLCs.

2019-11-14 | PXD014198 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data